B-Cell Maturation Antigen

Sikander Ailawadhi, MD, discusses positioning different therapies and navigate the treatment landscape in multiple myeloma.

Despite widespread vaccinations and preventive measures in place, the continued circulation of the COVID-19 virus remains a challenge for clinicians and patients affected by multiple myeloma.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Samer Al Hadidi, MD, MS, FACP, discusses research evaluating G protein–coupled receptor as a new target for therapy in relapsed refractory multiple myeloma.

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.

The FDA granted orphan drug designation to CT103A, a chimeric antigen receptor T-cell therapy in development for adults with relapsed or refractory multiple myeloma.

The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

The FDA cleared an investigational new drug application for P-BCMA-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma.